Literature DB >> 15545183

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types.

Kjell Oberg1, Lone Astrup, Barbro Eriksson, Sture E Falkmer, Ursula G Falkmer, Jens Gustafsen, Caj Haglund, Ulrich Knigge, Morten H Vatn, Matti Välimäki.   

Abstract

Part II of the guidelines contains a description of epidemiology, histopathology, clinical presentation, diagnostic procedure, treatment, and survival for each type of neuroendocrine tumour. We are not only including gastroenteropancreatic tumours but also bronchopulmonary and thymic neuroendocrine tumours. These guidelines essentially cover basic knowledge in the diagnosis and management of the different forms of neuroendocrine tumour. We have, however, tried to give more updated information about the epidemiology and histopathology, which is essential for the clinical management of these tumours.

Entities:  

Mesh:

Year:  2004        PMID: 15545183     DOI: 10.1080/02841860410018584

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  24 in total

1.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; A Couvelard; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

2.  Neuroendocrine neoplasms - still a challenge despite major advances in clinical care with the development of specialized guidelines.

Authors:  Stephan Petersenn; Christian A Koch
Journal:  Rev Endocr Metab Disord       Date:  2017-12       Impact factor: 6.514

3.  Synchronous gastric neuroendocrine carcinoma and hepatocellular carcinoma: a case report.

Authors:  Caroline Ewertsen; Birthe Merete Henriksen; Carsten Palnæs Hansen; Ulrich Knigge
Journal:  BMJ Case Rep       Date:  2009-09-15

Review 4.  Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.

Authors:  Omar Abdel-Rahman
Journal:  Tumour Biol       Date:  2014-09-18

Review 5.  Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.

Authors:  Gilles Poncet; Jean-Luc Faucheron; Thomas Walter
Journal:  World J Gastroenterol       Date:  2010-04-14       Impact factor: 5.742

6.  Consensus recommendations for the diagnosis and management of well-differentiated gastroenterohepatic neuroendocrine tumours: a revised statement from a Canadian National Expert Group.

Authors:  W Kocha; J Maroun; H Kennecke; C Law; P Metrakos; J F Ouellet; R Reid; C Rowsell; A Shah; S Singh; S Van Uum; R Wong
Journal:  Curr Oncol       Date:  2010-06       Impact factor: 3.677

7.  Gastric carcinoid in a patient infected with Helicobacter pylori: a new entity?

Authors:  Pantelis Antonodimitrakis; Apostolos Tsolakis; Staffan Welin; Gordana Kozlovacki; Kjell Oberg; Dan Granberg
Journal:  World J Gastroenterol       Date:  2011-07-07       Impact factor: 5.742

Review 8.  Medical treatment of gastrinomas.

Authors:  Christoph J Auernhammer; Burkhard Göke
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

9.  Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan.

Authors:  Tetsuhide Ito; Hironobu Sasano; Masao Tanaka; R Yoshiyuki Osamura; Iwao Sasaki; Wataru Kimura; Koji Takano; Takao Obara; Miyuki Ishibashi; Kazuwa Nakao; Ryuichiro Doi; Akira Shimatsu; Toshirou Nishida; Izumi Komoto; Yukio Hirata; Kazuhiko Nakamura; Hisato Igarashi; Robert T Jensen; Bertram Wiedenmann; Masayuki Imamura
Journal:  J Gastroenterol       Date:  2010-02       Impact factor: 7.527

Review 10.  Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.

Authors:  Omar Abdel-Rahman; Mona Fouad
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-03       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.